Here are the 424B prospectus supplements from Terns Pharmaceuticals, Inc. (TERN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TERN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TERN filings page.
Terns Pharmaceuticals, Inc. is offering 16,250,000 shares of common stock at $40.00 per share, for gross proceeds of $650,000,000 and estimated net proceeds of about $613.6 million.
The company also granted underwriters a 30-day option to buy up to 2,437,500 additional shares. As of September 30, 2025, 87,511,470 shares were outstanding, and Terns held $295.6 million of cash, cash equivalents and marketable securities. The new funds will be used to support research, clinical trials, development and manufacturing of key product candidates, including lead CML therapy TERN-701, initial activities for a potential future commercial launch of TERN-701, and for working capital and general corporate purposes. Based on current plans, Terns expects its cash, including this raise, to cover operating and capital needs at least into 2031.